Roivant Sciences Ltd at Evercore ISI HealthCONx Conference Transcript
Thank you guys for being here. Pleasure to have a management team from Roivant join us. You guys have a lot of cash, what you're planning on doing?
We do -- look, post the deal close, we will have roughly $7 billion. I think, look, that's an incredibly privileged place to be. In this interest rate environment, getting over 5% interest on that is not a bad place to be. And the deal hasn't closed. We said it's going to close towards the end of this year or beginning of next year, so don't have it yet. But look, we have -- our burn is roughly, what, 200 a quarter or so. We're spending that on the VTAMA launch and a lot of multiple late-stage clinical programs, we just had fantastic data on 1402 for an Anti-FcRn asset, that can obviously go pretty broad in terms of indications and there's a lot of things out there to be done in terms of deals, right?
I think, look, big pharma is going through a very unique period right now where there's a lot of EPS pressure and there's deals to be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
